Lu 38-012 is a potent and selective dopamine D4 receptor antagonist which has been used in scientific research. It has an affinity (Ki) for the dopamine D4.2 receptor of 7.5 nM and showed 16-fold selectivity for this receptor over the dopamine D2S receptor (Ki = 120 nM). The drug had relatively little affinity for other dopamine receptors. Affinities at other targets have also been reported. The drug produces hypolocomotion and reverses dextroamphetamine- and phencyclidine (PCP)-induced hyperlocomotion without producing catalepsy in rodents. Lu 38-012 partially substituted for clozapine in drug discrimination tests in rodents. It was developed by Lundbeck and was first described in the scientific literature by 2006.
See also Substituted phenylpiperazine Lu 35-138 Sonepiprazole
References


